



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 149 832 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:

31.10.2001 Bulletin 2001/44

(51) Int Cl.7: C07D 211/58, A61K 31/4468,
A61P 1/14

(21) Application number: 00902050.4

(86) International application number:
PCT/JP00/00560

(22) Date of filing: 02.02.2000

(87) International publication number:
WO 00/46201 (10.08.2000 Gazette 2000/32)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

- KADO, Noriyuki
Katsuyama-shi, Fukui 911-0813 (JP)
- SAKAGUCHI, Jun
Katsuyama-shi, Fukui 911-0813 (JP)

(30) Priority: 04.02.1999 JP 2703099


(74) Representative:
Sternagel, Fleischer, Godemeyer & Partner
Patentanwälte
An den Gärten 7
51491 Overath (DE)(71) Applicant: HOKURIKU SEIYAKU CO., LTD.
Katsuyama-shi, Fukui 911-0813 (JP)

(72) Inventors:

- KATO, Hideo
Katsuyama-shi, Fukui 911-0813 (JP)

(54) BENZAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME

(57) A novel benzamide derivative represented by the following general formula:



wherein R represents an alkyl group having 3 to 6 carbon atoms or a salt thereof, and a medicament comprising said derivative as an active ingredient. The medicament has excellent enhancing action on gastrointestinal tract motility, and is orally available with reduced side effects. Therefore, the medicament is extremely useful as an agent for therapeutic treatment of digestive diseases, an agent for improving function of gastrointestinal tract motility and the like.

EP 1 149 832 A1

Description**Field of the Invention**

- 5 [0001] The present invention relates to a novel benzamide derivative or a salt thereof which has an excellent enhancing effect on gastrointestinal tract motility and is useful as an agent for therapeutic treatment of digestive diseases, in particular, an agent for improving function of gastrointestinal tract motility.

Background Art

10

- [0002] Japanese Patent Unexamined Publication (Kokai) No. 5-262724/1993 filed by the present applicant discloses that 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetic acid and ethyl ester derivative thereof have enhancing actions on gastrointestinal tract functions (enhancing action on upper gastrointestinal tract motility and also enhancing action on lower gastrointestinal tract motility).

15

- [0003] The aforementioned known compounds have been revealed to have enhancing actions on motility of upper gastrointestinal tract and lower gastrointestinal tract. However, 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetic acid has a problem of insufficient oral absorbability. Ethyl ester derivative thereof also has a problem from viewpoints of efficacy and safety, e.g., the derivative is not suitable for oral administration because it causes undesirable side effects such as vomiting. Accordingly, it has been desired to develop a medicament which has improved oral 20 absorbability compared to 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidine-acetic acid, and has reduced or no side effect such as those caused by the ethyl ester derivative thereof.

Disclosure of the invention


25

- [0004] The inventors of the present invention conducted keen researches on the behavior of acetic acid esters of the aforementioned known benzamide derivative to solve the aforementioned problems. As a result, they found that novel benzamide derivatives of the present invention, i.e., ester derivatives of an alkyl having 3 to 6 carbon atoms that has a larger number of carbon atoms than that of the known benzamide derivative, had unexpectedly high enhancing effects on gastrointestinal tract motility. They also found that the emetic action caused by the ethyl ester derivative was reduced or eliminated in these compounds, and the compounds were extremely useful as an agent for therapeutic treatment of digestive diseases that can be administered orally, in particular, an agent for improving function of gastrointestinal tract motility such as a defecation stimulating agent. The present invention was achieved on the basis of these findings.

30

- [0005] The present invention thus relates to novel compounds represented by the following general formula (I) or salts thereof:

35



45

wherein R represents an alkyl group having 3 to 6 carbon atoms, preferably represents a straight or branched chain alkyl group having 3 to 6 carbon atoms.

50

- [0006] According to preferred embodiments of the present invention, there are provided compounds represented by the aforementioned general formula (I) wherein R represents an alkyl group having 4 to 5 carbon atoms, preferably a straight or branched chain alkyl group having 4 to 5 carbon atoms. For example, those having n-butyl group or n-pentyl group as R are provided.

55

- [0007] From another aspect of the present invention, there are provided medicaments comprising a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof as an active ingredient. The medicaments provided by the present invention are suitably used as, for example, a medicament for therapeutic and/or preventive treatment of digestive diseases, in particular, as a medicament for improving function of gastrointestinal tract motility.

- [0008] From further aspect of the present invention, there are provided a use of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof for the manufacture of the aforemen-

tioned medicaments; a method for therapeutic and/or preventive treatment of a digestive disease which comprises the step of administering to a mammal including a human a therapeutically and/or preventively effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; and a method for improving function of gastrointestinal tract motility which comprises the step of administering to a mammal including a human a therapeutically and/or preventively effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof.

5 Best mode for carrying out the invention

10 [0009] In the aforementioned general formula (I) according to the present invention, the alkyl group having 3 to 6 carbon atoms represented by R may be straight, branched, cyclic, or a combination thereof, and preferably a straight or branched chain alkyl group. Examples of the alkyl group having 3 to 6 carbon atoms include, for example, n-propyl group, isopropyl group, cyclopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, cyclobutyl group, cyclopropylmethyl group, n-pentyl group, isopentyl group, neopentyl group, tert-pentyl group, 1-cyclopropylethyl group, 2-cyclopropylethyl group, 2-methylcyclopropylmethyl group, cyclobutylmethyl group, n-hexyl group, isoheptyl group, cyclopentylmethyl group and the like. Examples of the straight or branched chain alkyl group include, for example, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, tert-pentyl group, n-hexyl group, isoheptyl group and the like.

15 [0010] The compounds represented by the aforementioned general formula (I) according to the present invention may be converted into salts, preferably physiologically acceptable salts, as required. The produced salts may further be converted into free base compounds. Examples of the salts of the compounds according to the present invention include acid addition salts. Examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid, salts with organic acids such as formic acid, acetic acid, propionic acid, butyric acid, valeric acid, pivalic acid, trifluoroacetic acid, acrylic acid, oleic acid, maleic acid, fumaric acid, citric acid, oxalic acid, succinic acid, tartaric acid, malic acid, malonic acid, lactic acid, glutaric acid, sebacic acid, gluconic acid, lauric acid, stearic acid, undecanoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, benzoic acid, phthalic acid, cinnamic acid, p-toluenesulfonic acid, nicotinic acid, picric acid, adipic acid, aspartic acid, glutamic acid, 10-camphorsulfonic acid, optically active substances thereof and the like.

20 [0011] The compounds represented by the aforementioned general formula (I) or salts thereof according to the present invention may exist as any crystal forms depending on manufacturing conditions, and they may also exist any hydrates or solvates. The crystal forms, hydrates, solvates, and mixtures thereof also fall within the scope of the present invention. In addition, the compounds represented by the aforementioned general formula (I) according to the present invention may have one or more asymmetric carbon atoms depending on type of R. Any optically active compounds or diastereomers based on one or more asymmetric carbon atoms, any mixtures thereof or racemates fall within the 25 scope of the present invention.

30 [0012] Specific examples of the compounds represented by the aforementioned general formula (I) according to the present invention include the following compounds and salts thereof. However, the present invention is not limited to these examples.

- 35
- 40 (1) n-Propyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate
 - (2) Isopropyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate
 - (3) n-Butyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate
 - (4) Isobutyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate
 - (5) n-Pentyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate

45 (6) Isopentyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate

 - (7) n-Hexyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate
 - (8) Isoheptyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate

50 [0013] Preferred compounds of the present invention include the following compounds.


- (1) n-Butyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate
- (2) n-Pentyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate

55 [0014] The compounds represented by the aforementioned general formula (I) of the present invention can be prepared, for example, by the methods explained below. However, the methods for preparing the compounds are not limited to these methods.

[0015] According to the first embodiment of preparation of the compounds of the present invention, a compound represented by the aforementioned general formula (I) can be prepared by allowing an amine compound represented

by the following formula (II):

5



10

to react in a solvent in the presence of a base with a compound represented by the following general formula (III):

15




wherein R has the same meaning as that defined above, and X represents a halogen atom or a leaving group such as p-toluenesulfonyloxy group and methanesulfonyloxy group.

[0016] The solvents used in the preparation may be any solvents so long as they does not inhibit the reaction. Examples include alcoholic solvents such as methanol, ethanol, isopropanol, tert-butanol, and 2-methoxyethanol, aromatic hydrocarbonic solvents such as benzene, toluene, and xylene, aprotic polar solvents such as ethyl acetate, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and dimethyl sulfoxide and the like. Examples of the base used include, for example, inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate and the like. The reaction may be performed within a temperature range of from room temperature to a refluxing temperature of a solvent.

[0017] According to the second embodiment of preparation of the compounds of the present invention, a compound represented by the aforementioned general formula (I) can be prepared by allowing a carboxylic acid compound represented by the following formula (IV):


30

35



to react with a carboxylic acid activator in a conventional manner to convert the carboxylic acid into an acid chloride, mixed acid anhydride or the like, and then allowing the resulting product to react in a solvent in the presence or absence of a base with an amine compound represented by the following general formula (V):

45




wherein R has the same meaning as that defined above.

[0018] Examples of the carboxylic acid activator used in the above preparation include, for example, thionyl chloride, oxalyl chloride, ethyl chloroformate, pivaloyl chloride, 1,1'-carbonyldiimidazole, 1,3-dicyclohexylcarbodiimide, propylphosphonic acid anhydride and the like. The solvents used may be any solvents so long as they does not inhibit the reaction. Examples include halogenated hydrocarbonic solvents such as methylene chloride, chloroform, and 1,2-dichloroethane, aromatic hydrocarbonic solvents such as benzene, toluene, and xylene, aprotic polar solvents such as ethyl acetate, acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and dimethyl sulfoxide and the like. Example of the base used include, for example, organic bases such as triethylamine, N,N-diisopropylethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, pyridine, and 4-dimethylaminopyridine, inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate and the

like. The reaction may be performed within a temperature range of from 0°C to a refluxing temperature of a solvent. [0019] According to the third embodiment of preparation of the compounds of the present invention, a compound represented by the aforementioned general formula (I) can be prepared by allowing a carboxylic acid compound represented by the following formula (VI):

5

10



15 to react in a solvent in the presence of a base with a compound represented by the following general formula (VII):



20 wherein R has the same meaning as that defined above, and Y represents a halogen atom or a leaving group such as p-toluenesulfonyloxy group and methanesulfonyloxy group.

[0020] The solvents used in the preparation may be any solvents so long as they do not inhibit the reaction. Examples include aprotic polar solvents such as ethyl acetate, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and dimethyl sulfoxide and the like. Example of the base used include, for example, inorganic bases such as sodium hydride, 25 sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate, and organic bases such as triethylamine, N,N-diisopropylethylamine, sodium methoxide, sodium ethoxide, 1,8-diazabicyclo[5.4.0]-7-undecene and the like. The reaction may be performed within a temperature range of from 0°C to a refluxing temperature of a solvent.

[0021] According to the fourth embodiment of preparation of the compounds of the present invention, a compound 30 represented by the aforementioned general formula (I) can be prepared by allowing a carboxylic acid compound represented by the aforementioned formula (VI) to react in the presence of an acid catalyst with an alcohol compound represented by the following general formula (VIII):

35



wherein R has the same meaning as that defined above.

[0022] Examples of the acid catalyst used in the preparation include, for example, hydrogen chloride, sulfuric acid, 40 methanesulfonic acid, p-toluenesulfonic acid and the like. The alcohol compound represented by the aforementioned general formula (VIII) is used in a large excess amount so that it can also serve as a reaction solvent. The reaction is performed within a temperature range of from room temperature to a refluxing temperature of a solvent.

[0023] The starting materials used for the preparation of the compounds of the present invention are known compounds with a few exceptions. As for novel compounds, their preparations are described as Reference Examples.

[0024] The medicaments comprising as an active ingredient the compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof according to the present invention are generally administered 45 as preparations for oral administration such as capsules, tablets, subtilized granules, granules, powders and syrups, or preparations for parenteral administration such as suppositories. These preparations can be manufactured in a conventional manner by adding one or more of pharmacologically or pharmaceutically acceptable additives to the compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof according to the present invention. As the pharmacologically or pharmaceutically acceptable additives used for preparations for oral administration or suppositories, additives for pharmaceutical preparations such as, for example, excipients such as lactose, D-mannitol, sucrose, corn starch, and crystalline cellulose; disintegrators such as carboxymethylcellulose, calcium carboxymethylcellulose, partly pregelatinized starch, croscarmellose sodium, and crospovidone; binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, and polyvinylpyrrolidone; lubricants such as magnesium 50 stearate, talc, hydrogenated oil, dimethylpolysiloxane, hydrated silicon dioxide, colloidal silicon dioxide, and carnauba wax; plasticizers such as triethyl citrate, fatty acid glycerin esters, and polyethylene glycol; coating agents such as hydroxypropylmethylcellulose, sucrose, and titanium oxide; bases such as polyethylene glycol, and hard fat and the like may be used.

EP 1 149 832 A1

[0025] Doses of the medicament of the present invention may vary depending on symptoms or the age of a patient and the like. Generally, a dose for an adult in an amount of 0.1 to 500 mg for oral administration, or 0.01 to 300 mg for parenteral administration may be administered once or several times as divided portions in a day.

5 EXAMPLES

[0026] The present invention will be further explained with reference to the examples. However, the present invention is not limited to any specific details described in these examples.

10 Example 1: n-Butyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate methanesulfonate

[0027] A mixture of 68.0 g of 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetic acid, 27.5 g of potassium carbonate and 510 ml of dry N,N-dimethylformamide was stirred at 60°C of outer temperature for 1.5 hours, and added dropwise with a solution of 22.4 ml of n-butyl bromide in 26 ml of dry N,N-dimethylformamide. The mixture was further stirred at the same temperature for 1.5 hours. The mixture was added with water, and extracted with ethyl acetate. The extract was washed successively with water and saturated aqueous sodium chloride solution, dried, and then the solvent was evaporated. The residue was added with n-heptane, and precipitated crystals were collected by filtration to obtain 57.6 g of colorless crystals. Methanesulfonate of the product was prepared in a conventional manner, and recrystallized from moist isopropanol to obtain colorless crystals (mp: 209-211.5°C).

20

Analysis for C ₁₉ H ₂₈ ClN ₃ O ₄ · CH ₄ O ₃ S			
Calculated %	C, 48.63;	H, 6.53;	N, 8.51
Found %	C, 48.37;	H, 6.81;	N, 8.44

25

[0028] In the same manner as described in Example 1, the compounds of Example 2 through 7 were obtained.

Example 2: n-Propyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate methanesulfonate

30 [0029]

Appearance: colorless needles (isopropanol)

mp: 209-210°C

35

Analysis for C ₁₈ H ₂₆ ClN ₃ O ₄ · CH ₄ O ₃ S			
Calculated %	C, 47.54;	H, 6.30;	N, 8.75
Found %	C, 47.47;	H, 6.41;	N, 8.69

40

Example 3: Isopropyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate hydrochloride

[0030]

45

Appearance: colorless needles (isopropanol)

mp: 125-130°C

50

Analysis for C ₁₈ H ₂₆ ClN ₃ O ₄ · HCl · 2H ₂ O			
Calculated %	C, 47.37;	H, 6.85;	N, 9.21
Found %	C, 47.46;	H, 6.67;	N, 9.14

Example 4: Isobutyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate methanesulfonate

55 [0031]

Appearance: colorless needles (isopropanol)

mp: 207-208°C

5

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · CH ₄ O ₃ S · 1/4H ₂ O			
Calculated %	C, 48.19;	H, 6.57;	N, 8.43
Found %	C, 48.14;	H, 6.80;	N, 8.36

Example 5: n-Pentyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate <Methanesulfonate>

10

[0032]

Appearance: colorless needles (isopropanol)
mp: 202.5-203°C

15

Analysis for C ₂₀ H ₃₀ CIN ₃ O ₄ · CH ₄ O ₃ S			
Calculated %	C, 49.65;	H, 6.75;	N, 8.27
Found %	C, 49.46;	H, 6.98;	N, 8.22

20

<L-Tartrate>

[0033]

25

Appearance: colorless needles (isopropanol)
mp: 155.5-156.5°C

30

Analysis for C ₂₀ H ₃₀ CIN ₃ O ₄ · C ₄ H ₆ O ₆			
Calculated %	C, 51.29;	H, 6.46;	N, 7.48
Found %	C, 51.13;	H, 6.30;	N, 7.40

Example 6: Isopentyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate methanesulfonate

35

[0034]

Appearance: colorless needles (isopropanol)
mp: 199.5-201°C

40

Analysis for C ₂₀ H ₃₀ CIN ₃ O ₄ · CH ₄ O ₃ S · 3/4H ₂ O			
Calculated %	C, 48.36;	H, 6.86;	N, 8.06
Found %	C, 48.24;	H, 6.64;	N, 8.02

45

Example 7: n-Hexyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate hydrochloride

50

[0035]

Appearance: colorless plates (isopropanol)
mp: 133-137°C

55

Analysis for C ₂₁ H ₃₂ CIN ₃ O ₄ · HCl · 1/2H ₂ O			
Calculated %	C, 53.50;	H, 7.27;	N, 8.91
Found %	C, 53.26;	H, 7.27;	N, 8.82

EP 1 149 832 A1

Example 8: n-Butyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate hydrochloride

[0036] To a suspension of 5.00 g of 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetic acid in 75 ml of n-butanol, 1.80 g of sulfuric acid was added, and the mixture was refluxed for 3 hours. The solvent of the reaction mixture was evaporated, and the residue was adjusted to pH 9 to 10 by addition of aqueous potassium carbonate solution. Then, the mixture was extracted with methylene chloride. The extract was washed with saturated aqueous sodium chloride solution, dried, and then the solvent was evaporated. The residue was added with water, and adjusted to pH 2 with 10% hydrochloric acid. The precipitated crystals were collected by filtration, and washed successively with water and diisopropyl ether to obtain 5.51 g of pale yellow crystals. The crystals were recrystallized from n-butanol to obtain pale brown needles (mp: 133-136.5°C). The crystals were further recrystallized from isopropanol to obtain colorless needles (mp: 141-144°C).

15

Analysis for $C_{19}H_{28}ClN_3O_4 \cdot HCl \cdot H_2O$			
Calculated %	C, 50.45;	H, 6.91;	N, 9.29
Found %	C, 50.37;	H, 6.58;	N, 9.26

Reference Example 1: n-Butyl 4-tert-butoxycarbonylamino-1-piperidineacetate

20

[0037] A suspension of 1.00 g of 4-(tert-butoxycarbonylamino)piperidine and 0.72 ml of triethylamine in 6 ml of dry N,N-dimethylformamide was stirred at an inner temperature of 50°C, and added dropwise with a solution of 0.79 g of n-butyl chloroacetate in 4 ml of dry N,N-dimethylformamide. Stirring was continued at the same temperature for 1 hour. Then, the reaction mixture was added with water, and the precipitated crystals were collected by filtration. The crystals were washed successively with water and n-heptane to obtain 1.46 g of colorless scales (mp: 115.5-116.5°C).

25

Analysis for $C_{16}H_{30}N_2O_4$			
Calculated %	C, 61.12;	H, 9.62;	N, 8.91
Found %	C, 60.90;	H, 9.60;	N, 8.88

30

Reference Example 2: n-Butyl 4-amino-1-piperidineacetate

35

[0038] A solution of hydrogen chloride in isopropanol (6 ml) was added to 1.35 g of n-butyl 4-tert-butoxycarbonylamino-1-piperidineacetate, and the mixture was stirred at room temperature for 15 minutes. The solvent was evaporated, and the residue was added with 5 ml of tetrahydrofuran and 1.3 ml of triethylamine. The precipitated solid was filtered off, and the solvent of the filtrate was evaporated to obtain 1.04 g of colorless oil.

Mass spectrum m/z : 214 (M⁺)

IR spectrum v (liq) cm⁻¹ : 2960, 2940, 1746

40

NMR spectrum δ (CDCl₃) ppm : 0.93 (3H, t, J=7.5Hz), 1.37 (2H, sex, J=7.5Hz), 1.45-1.55 (2H, m), 1.55-1.65 (2H, m), 1.86 (2H, d, J=12Hz), 2.02 (2H, brs), 2.20-2.30 (2H, m), 2.65-2.75 (1H, m), 2.90 (2H, d, J=12Hz), 3.21 (2H, s), 4.12 (2H, t, J=7.5Hz)

Example 9: n-Butyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetate < Methanesulfonate >

45

[0039] To a suspension of 1065 g of 4-amino-5-chloro-2-methoxybenzoic acid in 11 L of dry tetrahydrofuran, 821 ml of triethylamine was added, and the mixture was stirred under ice cooling for 1 hour. The reaction mixture was added dropwise with 526 ml of ethyl chloroformate, and stirred under ice cooling for 1.5 hours. The reaction mixture was added with a solution of 1260 g of n-butyl 4-amino-1-piperidineacetate in 2.4 L of dry tetrahydrofuran, and stirred under ice cooling for 2 hours. The precipitated solid was filtered off, and the solvent of the filtrate was evaporated. The residue was added with aqueous potassium carbonate solution, and extracted with methyl isobutyl ketone. The extract was washed with saturated aqueous sodium chloride solution, dried, and then the solvent was evaporated. The residue was washed with diisopropyl ether to obtain 1759 g of colorless crystals (free base). Methanesulfonate of the product was prepared in a conventional manner, and recrystallized from moist isopropanol to obtain colorless crystals (mp: 209-211.5°C). The compound obtained was identical to the compound obtained in Example 1 in IR spectrum and NMR spectrum.

[0040] Using the above-mentioned free base, the following acid addition salts were prepared in a conventional manner.

<Hydrobromide>

[0041]

- 5 Appearance: colorless needles (isopropanol)
 mp: 198-201°C

Analysis for $C_{19}H_{28}ClN_3O_4 \cdot HBr \cdot H_2O$			
Calculated %	C, 45.93; C, 45.85;	H, 6.29; H, 6.09;	N, 8.46 N, 8.41
Found %			

<Nitrate>

[0042]

- Appearance: yellow prisms (isopropanol)
 mp: 168-170°C

Analysis for $C_{19}H_{28}ClN_3O_4 \cdot HNO_3$			
Calculated %	C, 49.51; C, 49.52;	H, 6.34; H, 6.20;	N 12.16 N 12.10
Found %			

25 <Sulfate>

[0043]

- 30 Appearance: colorless needles (moist isopropanol)
 mp: 220-223°C (decomposition)

Analysis for $C_{19}H_{28}ClN_3O_4 \cdot H_2O_4S$			
Calculated %	C, 46.01; C, 45.99;	H, 6.10; H, 5.93;	N, 8.47 N, 8.38
Found %			

<Phosphate>

40 [0044]

- Appearance: colorless needles (isopropanol)
 mp: 100-104°C

Analysis for $C_{19}H_{28}ClN_3O_4 \cdot H_3O_4P \cdot 1/4H_2O$			
Calculated %	C, 45.60; C, 45.54;	H, 6.35; H, 6.08;	N, 8.40 N, 8.40
Found %			

50 <Fumarate>

[0045]

- 55 Appearance: colorless prisms (isopropanol)
 mp: 178-180°C

5

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₄ H ₄ O ₄			
Calculated %	C, 53.75;	H, 6.28;	N, 8.18
Found %	C, 53.49;	H, 6.09;	N, 8.15

<Maleate>

10

[0046]

Appearance: colorless prisms (isopropanol)
 mp: 124-126°C

15

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₄ H ₄ O ₄ · 1/2H ₂ O			
Calculated %	C, 52.82;	H, 6.36;	N, 8.03
Found %	C, 52.60;	H, 6.19;	N, 8.07

20

<p-Toluenesulfonate>

[0047]

25

Appearance: colorless needles (isopropanol)
 mp: 208-211°C

30

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₇ H ₈ O ₃ S			
Calculated %	C, 54.78;	H, 6.36;	N, 7.37
Found %	C, 54.55;	H, 6.34;	N, 7.35

<L-Tartrate>

35

[0048]

Appearance: colorless prisms (isopropanol)
 mp: 186-187°C (decomposition)

40

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₄ H ₆ O ₆			
Calculated %	C, 50.41;	H, 6.25;	N, 7.67
Found %	C, 50.14;	H, 6.13;	N, 7.57

45

<Malonate>

50

[0049]

Appearance: colorless prisms (isopropanol-diisopropyl ether)
 mp: 105-106°C

55

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₃ H ₄ O ₄ · 1/2H ₂ O			
Calculated %	C, 51.71;	H, 6.51;	N, 8.08
Found %	C, 51.41;	H, 6.24;	N, 8.18

<Succinate>

[0050]

- 5 Appearance: colorless prisms (isopropanol-diisopropyl ether)
 mp: 110-111°C

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₄ H ₆ O ₄			
Calculated %	C, 53.54; C, 53.34;	H, 6.64; H, 6.50;	N, 8.14 N, 8.11
Found %			

<D-(+)-Malate>

[0051]

- Appearance: colorless prisms (isopropanol-diisopropyl ether)
 mp: 111-112°C

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₄ H ₆ O ₅			
Calculated %	C, 51.93; C, 51.76;	H, 6.44; H, 6.28;	N, 7.90 N, 7.93
Found %			

<L-(-)-Malate>

[0052]

- 30 Appearance: colorless prisms (isopropanol-diisopropyl ether)
 mp: 111-112°C

Analysis for C ₁₉ H ₂₈ CIN ₃ O ₄ · C ₄ H ₆ O ₅			
Calculated %	C, 51.93; C, 51.71;	H, 6.44; H, 6.30;	N, 7.90 N, 7.87
Found %			

Formulation Example 1 (Tablet)

- 40 **[0053]** The following ingredients were mixed in a conventional manner to manufacture a tablet.

45	Compound of Example 1 (or 9)	5 mg
	Lactose	Sufficient Quantity
	Corn starch	15 mg
	Polyvinylpyrrolidone	2 mg
	Magnesium stearate	1 mg
	Hydroxypropylmethylcellulose	4 mg
	Polyethyleneglycol	0.5 mg
	Titanium oxide	0.5 mg
		100 mg

Formulation Example 2 (Capsule)

- 55 **[0054]** The following ingredients were mixed in a conventional manner, and filled into a hard capsule to manufacture a capsule.

5

Compound of Example 9	10 mg
Lactose	Sufficient Quantity
Calcium carboxymethylcellulose	5 mg
Hydroxypropylcellulose	1 mg
Magnesium stearate	1 mg
	80 mg

10 Formulation Example 3 (Powder)

[0055] The following ingredients were mixed in a conventional manner to manufacture powder.

15

20

Compound of Example 9	10 mg
Lactose	Sufficient Quantity
D-Mannitol	500 mg
Hydroxypropylcellulose	20 mg
Talc	2 mg
	1000 mg

Formulation Example 4 (Suppository)

25

30

35

[0056] The following ingredients were mixed in a conventional manner to manufacture a suppository.

Compound of Example 9	5 mg
Hard Fat	1295 mg
	1300 mg

[0057] Effects on colonic motility in conscious dogs are shown as examples demonstrating superior effects of compounds of the present invention, and test results demonstrating their emetic actions in ferrets are also shown as a side effect. The tested compound of Example 5 was used as a methanesulfonic acid salt, and the following compounds disclosed in Japanese Patent Unexamined Publication No. 5-262724/1993 were used as reference compounds:

40

Reference compound 1: 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidineacetic acid hydrochloride,
Reference compound 2: Ethyl 4-(4-amino-5-chloro-2-methoxybenzamido)-1-piperidine-acetate hydrochloride.

45

Test Example 1 : Effect on colonic motility in conscious dogs

50

55

[0058] According to the method of Itoh et al. (Japanese J. Smooth Muscle Research, vol. 13, p.33, 1976; or Gastro-enterologia Japonica, vol. 12, No 4, p.18, 1977) a strain-gauge force transducer was chronically sutured on ascending colon of beagle dogs of both sexes weighing 7.9 to 12.0 kg under general anesthesia in a direction that enabled measurement of circular muscle contractions of a portion of the ascending colon 10 cm distal from the cecum in the anus. A sailastic cannula was implanted in the duodenal wall to use as a catheter for intra-duodenal administration. After 2 weeks or more of the surgery, test compounds dissolved in saline containing 1% lactic acid were administered intra-duodenally (i.d.) to the beagle dogs 2 hours or more after feeding. Appearances of giant contractions in the ascending colon during 40 minutes after the administration were observed. The results are shown in Table 1.

60

65

Table 1

Tested Compound	Number of tested dogs	Dose (mg/kg, i.d.)	Number of dogs showing colonic giant contraction
Control	5	0	0
Example 1	4	1.0	4
Example 2	5	1.0	4

Table 1 (continued)

Tested Compound	Number of tested dogs	Dose (mg/kg, i.d.)	Number of dogs showing colonic giant contraction
Example 4	5	1.0	5
Example 5	5	1.0	4
Example 7	5	1.0	4
Reference compound 1	5 6	1.0	0
Reference compound 2	4	1.0	4

[0059] The compounds of the present invention exhibited extremely strong colonic contracting effect compared to the reference compound 1 by intra-duodenal administration, and almost comparable colonic contracting effect to that of the reference compound 2.

Test Example 2: Emetic action in ferrets

[0060] Each test compound dissolved in 10% aqueous dimethyl sulfoxide solution was administered to male ferrets, weighing 0.9 to 1.3 kg, and 16 hours fasting, and then the incidence of vomiting was observed during 2 hours after the administration. The results are shown in Table 2.

Table 2

Tested Compound	Number of tested ferrets	Dose (mg/kg, p.o.)	Number of ferrets showing vomiting
Control	8	0	0
Example 1	8	10	0
Example 2	8	10	2
Example 4	8	10	1
Example 5	8	10	0
Example 7	8	10	1
Reference compound 1	8	10	0
Reference compound 2	8	10	8


[0061] Incidence of vomiting observed for orally administered reference compound 2 was not induced or very slightly induced by the compounds of the present invention.

Industrial Applicability

[0062] The novel benzamide derivatives or salts thereof have excellent enhancing effects on gastrointestinal tract motility and are orally available with reduced side effects, and accordingly, they are extremely useful as medicaments for therapeutic and/or preventive treatment of digestive diseases, or agents for improving function of gastrointestinal tract motility such as defecation stimulating agents.

Claims

1. A compound represented by the following general formula:



wherein R represents an alkyl group having 3 to 6 carbon atoms, or a salt thereof.

- 15
2. The compound or the salt thereof according to claim 1 wherein R is a straight or branched chain alkyl group having 3 to 6 carbon atoms.
 3. The compound or the salt thereof according to claim 1 wherein R is a straight or branched chain alkyl group having 4 to 5 carbon atoms.
 4. The compound or the salt thereof according to claim 1 wherein R is n-butyl group or n-pentyl group.
 5. A medicament which comprises a compound or a physiologically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.
 - 20
 6. The medicament according to claim 5 which is used for therapeutic and/or preventive treatment of a digestive disease.
 - 25
 7. The medicament according to claim 5 which is used for improvement of function of gastrointestinal tract motility.
 8. An agent for improving function of gastrointestinal tract motility which comprises a compound or a physiologically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.
 - 30
 9. A use of a compound or a physiologically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of a medicament according to claim 6 or claim 7.
 - 35
 10. A method for therapeutic and/or preventive treatment of a digestive disease which comprises the step of administering to a mammal including a human a therapeutically and/or preventively effective amount of a compound or a physiologically acceptable salt thereof according to any one of claims 1 to 4.
 - 40
 11. A method for improving function of gastrointestinal tract motility which comprises the step of administering to a mammal including a human a therapeutically and/or preventively effective amount of a compound or a physiologically acceptable salt thereof according to any one of claims 1 to 4.

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/00560

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 10,11
because they relate to subject matter not required to be searched by this Authority, namely:
The subject matter of claims 10 and 11 relates to a "method for treatment of the human body by operation or therapy" stipulated in PCT Rule 39.1(iv).

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT		International application No. PCT/JP00/00560
A. CLASSIFICATION OF SUBJECT MATTER Int.Cl' C07D211/58, A61K31/4468, A61P1/14		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl' C07D211/58, A61K31/4468, A61P1/14		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN) REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, 640601, A (HOKURIKU SEIYAKU CO., LTD.), 01 March, 1995 (01.03.95) & WO, 640601, A1 & JP, 5-262724, A & US, 5395832, A & US, 5500422, A	1-9
PA	JP, 11-292846, A (HOKURIKU SEIYAKU CO., LTD.), 26 October, 1999 (26.10.99) (Family: none)	1-9
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "T" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 01 May, 2000 (01.05.00)	Date of mailing of the international search report 16 May, 2000 (16.05.00)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Faxsimile No.	Telephone No.	

Form PCT/ISA/210 (second sheet) (July 1992)